Fate Therapeutics Inc (FATE) stock
FATENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3019% above fair value
$1.34−0.26 (-16.51%)
Close on Nov 12, 2026Market cap $160.56MP/E –Yield –
Fate Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Fate Therapeutics's profit margin for the twelve months ending Sep 30, 2026 was -2619.6%. For fiscal 2025 it was -2051.1%, against -1366.5% the year before. The highest annual figure on record is -253.3% in fiscal 2023.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -2051.1% | −684.6 |
| FY2024 | Dec 31, 2024 | -1366.5% | −1113.2 |
| FY2023 | Dec 31, 2023 | -253.3% | +39.2 |
| FY2022 | Dec 31, 2022 | -292.5% | +87.3 |
| FY2021 | Dec 31, 2021 | -379.9% | +171.7 |
| FY2020 | Dec 31, 2020 | -551.6% | +367.4 |
| FY2019 | Dec 31, 2019 | -919.0% | +486.0 |
| FY2018 | Dec 31, 2018 | -1405.0% | −358.9 |
| FY2017 | Dec 31, 2017 | -1046.1% | −285.9 |
| FY2016 | Dec 31, 2016 | -760.2% | +473.6 |
| FY2015 | Dec 31, 2015 | -1233.7% | +918.1 |
| FY2013 | Dec 31, 2013 | -2151.8% | −1618.5 |
| FY2012 | Dec 31, 2012 | -533.3% | +614.3 |
| FY2011 | Dec 31, 2011 | -1147.6% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -1448.6% | +338.0 |
| Q1 FY2026 | Mar 31, 2026 | -2402.8% | −93.4 |
| Q4 FY2025 | Dec 31, 2025 | -2364.8% | +439.1 |
| Q3 FY2025 | Sep 30, 2025 | -1852.4% | −301.4 |
| Q2 FY2025 | Jun 30, 2025 | -1786.6% | −1219.1 |
| Q1 FY2025 | Mar 31, 2025 | -2309.5% | +184.3 |
| Q4 FY2024 | Dec 31, 2024 | -2803.9% | −171.3 |
| Q3 FY2024 | Sep 30, 2024 | -1551.0% | +772.6 |
| Q2 FY2024 | Jun 30, 2024 | -567.4% | +5086.9 |
| Q1 FY2024 | Mar 31, 2024 | -2493.7% | −2461.7 |
| Q4 FY2023 | Dec 31, 2023 | -2632.6% | −2505.5 |
| Q3 FY2023 | Sep 30, 2023 | -2323.6% | −1765.8 |
| Q2 FY2023 | Jun 30, 2023 | -5654.3% | −5244.0 |
| Q1 FY2023 | Mar 31, 2023 | -32.0% | +324.7 |
| Q4 FY2022 | Dec 31, 2022 | -127.1% | +275.0 |
| Q3 FY2022 | Sep 30, 2022 | -557.8% | −253.3 |
| Q2 FY2022 | Jun 30, 2022 | -410.3% | +0.8 |
| Q1 FY2022 | Mar 31, 2022 | -356.7% | +47.9 |
| Q4 FY2021 | Dec 31, 2021 | -402.0% | −67.9 |
| Q3 FY2021 | Sep 30, 2021 | -304.4% | +472.0 |
| Q2 FY2021 | Jun 30, 2021 | -411.1% | +102.6 |
| Q1 FY2021 | Mar 31, 2021 | -404.7% | +928.1 |
| Q4 FY2020 | Dec 31, 2020 | -334.1% | +675.9 |
| Q3 FY2020 | Sep 30, 2020 | -776.4% | +319.0 |
| Q2 FY2020 | Jun 30, 2020 | -513.7% | +319.8 |
| Q1 FY2020 | Mar 31, 2020 | -1332.8% | −582.0 |
| Q4 FY2019 | Dec 31, 2019 | -1010.1% | −45.2 |
| Q3 FY2019 | Sep 30, 2019 | -1095.5% | +540.2 |
| Q2 FY2019 | Jun 30, 2019 | -833.4% | +1080.3 |
| Q1 FY2019 | Mar 31, 2019 | -750.8% | +626.9 |
| Q4 FY2018 | Dec 31, 2018 | -964.9% | +251.9 |
| Q3 FY2018 | Sep 30, 2018 | -1635.7% | −594.3 |
| Q2 FY2018 | Jun 30, 2018 | -1913.7% | −973.7 |
| Q1 FY2018 | Mar 31, 2018 | -1377.7% | −391.7 |
| Q4 FY2017 | Dec 31, 2017 | -1216.8% | −443.7 |
| Q3 FY2017 | Sep 30, 2017 | -1041.3% | – |
| Q2 FY2017 | Jun 30, 2017 | -940.1% | – |
| Q1 FY2017 | Mar 31, 2017 | -986.0% | – |
| Q4 FY2016 | Dec 31, 2016 | -773.1% | – |
See a number that looks wrong?